COVID-19: US FDA authorises Novavax vaccine for emergency use in adults
World | Jul 14, 2022, 07:39 AM ISTCOVID-19: For now, the FDA authorized Novavax’s initial two-dose series for people 18 and older.
COVID-19: For now, the FDA authorized Novavax’s initial two-dose series for people 18 and older.
In addition, the scientists tested the ability of 19 monoclonal antibody treatments to neutralise the variants and found that only one of the available antibody treatments remained highly effective against both Omicron sub-variants BA.2.12.1 and BA.4/5.
Krishna was in Paris as a speaker at Viva Technology 2022 where India was declared country of the year.
A total of 1,15,656 precaution doses of Covid vaccines were administered among those aged 18-59 years till 7pm on Tuesday, taking the tally of such jabs given in this age group to 39,00,663, according to the Health Ministry data.
WTO Director-General Nzogi Okonjo-Iweala, after a pair of sleepless nights in rugged negotiations, concluded the WTO’s first ministerial conference in 4-1/2 years by trumpeting a new sense of cooperation at a time when the world has faced crises like growing food insecurity, war in Ukraine and a once-in-a-century pandemic that has taken millions of lives.
The findings of the study have been published on Tuesday on bioRxiv, a pre-print server and have not been peer-reviewed.
This means that any adult can take the booster shot after two doses of Covishield or Covaxin.
The COVID-19 vaccination for the age group 12-14 years was started on March 16 and so far more than 3.30 crore adolescents in this age group have been administered the first dose.
Strap: More than 60 per cent of youngsters between 15 and 18 years of age have been fully vaccinated against Covid-19, Union Health Minister Mansukh Mandaviya announced on Friday.
Previously, in private vaccination centres the overall cost to end users of the vaccine was Rs 990 a dose, including taxes and administration charges, it added.
A total of 38,476 precaution doses of the vaccines were administered to beneficiaries aged 18-59 years till 7 pm, taking the total number of such doses given in this age-group to 11,78,161, according to the ministry's data.
COVID19: Scientist says that instead of trying to make a vaccine each time a new variant emerges, it is best to develop something that can curb the spread and not harm people.
Serum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry recently, requesting for Covovax's inclusion in the immunisation drive for children aged 12 to 17 years.
Chief Medical Officer of Lakhimpur Kheri Dr Shailendra Bhatnagar said the dose Shivam Jaiswal received would serve as a "precautionary dose against rabies".
India's Active Caseload currently stands at 15,873 and the active cases now constitute 0.04 per cent of the country's total positive cases.
The study found that a fourth dose can reduce the possibilities of symptomatic infection, hospitalisation, serious illness and mortality among the elders.
After the announcement, vaccine maker Serum Institute of India (SII) said the precaution dose of its Covishield vaccine will be priced at Rs 600 per shot for eligible individuals.
SII CEO Adar Poonawalla also welcomed the government’s move to allow precaution dose of the vaccine to all aged above 18 years at private vaccination centres, saying it will further provide long-term protection against the virus, and aid ease of travel.
India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12-17 age group, subject to certain conditions, on March 9.
"This evidence shows that vaccination reduces this risk substantially in 5 to 11-year-olds. And while vaccination provided adolescents with lower protection against hospitalisation with Omicron versus Delta, it prevented critical illness from both variants," the researcher said.
Top News
Latest News